New Issue: Science’s Impossible Questions. Read Now

New Tricks for an Old Drug

Join Our Community of Science Lovers!

To date, the drug sulindac has seen two primary uses: treating such inflammatory diseases as rheumatoid arthritis and preventing the growth of potentially precancerous colon polyps. But in today¿s Proceedings of the National Academy of Sciences, researchers from New York report yet another indication: sulindac may help prevent the narrowing of arteries after angioplasty¿a procedure that involves widening blood vessels blocked by atherosclerosis using a tiny balloon or stent. Angioplasty works well in the short term, but it can injure the artery wall. In these cases, the injury probably leads to an inflammatory response, which in turn stimulates the growth of smooth muscle cells that narrow the vessel all over again.

To test sulindac's effects in mice, the authors injured an artery in the upper leg of the animals using a procedure similar to angioplasty and then gave sulindac to some animals, aspirin to others and no treatment to a third group. After four weeks, they found that mice receiving sulindac showed considerably less thickening of their artery walls than the others. The effect was even more pronounced in mice that, as the result of a genetic defect, had very high blood cholesterol levels. (Most patients who undergo angioplasty also have high blood cholesterol levels.) These mice, when untreated, showed more than twice as much wall thickening as normal mice. Yet after treatment with sulindac, their arterial walls were the same size as those of normal mice receiving the drug.

The reasearchers do not know why sulindac worked and aspirin did not. Both are nonsteroid, anti-inflammatory agents, known to inhibit an enzyme called cyclooxygenase. The only guess so far is that sulindac might have additional effects, including inhibiting macrophages, or the growth of smooth muscles cells or endothelial cells. Whatever the mechanism, sulindac might help people who have undergone angioplasty avoid having their arteries clog up again.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


 

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe